Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.8% - Here's Why

Key Points

• Compass Therapeutics' shares increased by 4.8%, reaching a high of $4.21 and last trading at $4.27, despite a decline in trading volume compared to average session volumes.
• Analysts have provided positive ratings for Compass Therapeutics, with targets ranging from $9.00 to $32.00, and a consensus rating of "Moderate Buy" with a target price of $13.10.
• The company reported a quarterly loss of (0.14) earnings per share, which was worse than analysts' estimates, prompting predictions of further losses for the current year.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) shot up 4.8% on Friday . The company traded as high as $4.21 and last traded at $4.27. 1,379,223 shares traded hands during trading, a decline of 3% from the average session volume of 1,417,234 shares. The stock had previously closed at $4.07.

Analyst Ratings Changes

Several analysts have recently commented on CMPX shares. Lifesci Capital started coverage on Compass Therapeutics in a report on Monday. They set an "outperform" rating and a $10.00 price objective for the company. D. Boral Capital reiterated a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday, August 12th. Raymond James Financial upgraded Compass Therapeutics to an "outperform" rating and set a $9.00 price objective for the company in a report on Tuesday, July 1st. Guggenheim increased their price objective on Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Compass Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Compass Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $13.10.

Compass Therapeutics Price Performance

The business has a fifty day moving average price of $3.33 and a two-hundred day moving average price of $2.63. The firm has a market capitalization of $584.23 million, a price-to-earnings ratio of -9.38 and a beta of 1.48.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). On average, research analysts predict that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Creative Planning acquired a new stake in Compass Therapeutics during the 2nd quarter worth about $30,000. Strs Ohio acquired a new stake in Compass Therapeutics during the 1st quarter worth about $34,000. Birchview Capital LP acquired a new stake in Compass Therapeutics during the 1st quarter worth about $46,000. Walleye Trading LLC acquired a new stake in Compass Therapeutics during the 1st quarter worth about $48,000. Finally, Vontobel Holding Ltd. acquired a new stake in Compass Therapeutics during the 1st quarter worth about $57,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.